StockData
Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc. (MLYS) stock

MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.78−0.70 (-4.83%)

Close on Nov 18, 2026Market cap $1.22BP/E –Yield –

Mineralys Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Mineralys Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$370.79M. For fiscal 2025 it was -$170.60M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$170.60M–
FY2024Dec 31, 2024-$192.40M–
FY2023Dec 31, 2023-$84.66M–
FY2022Dec 31, 2022-$31.48M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$246.04M–
Q1 FY2026Mar 31, 2026-$45.34M–
Q4 FY2025Dec 31, 2025-$38.28M–
Q3 FY2025Sep 30, 2025-$41.13M–
Q2 FY2025Jun 30, 2025-$46.75M–
Q1 FY2025Mar 31, 2025-$44.45M–
Q4 FY2024Dec 31, 2024-$51.77M–
Q3 FY2024Sep 30, 2024-$60.11M–
Q2 FY2024Jun 30, 2024-$45.17M–
Q1 FY2024Mar 31, 2024-$35.36M–
Q4 FY2023Dec 31, 2023-$27.71M–
Q3 FY2023Sep 30, 2023-$26.27M–
Q2 FY2023Jun 30, 2023-$15.74M–
Q1 FY2023Mar 31, 2023-$14.94M–
Q4 FY2022Dec 31, 2022-$10.01M–
Q3 FY2022Sep 30, 2022-$7.42M–
Q2 FY2022Jun 30, 2022-$6.48M–
Q1 FY2022Mar 31, 2022-$7.57M–

More Mineralys Therapeutics figures

See a number that looks wrong?